PT-141 (bremelanotide) is a synthetic melanocortin peptide that acts on central nervous system pathways to support sexual desire and arousal. At TelosRX, access is subject to medical approval by a licensed provider through our asynchronous telehealth process.
Interest in PT-141 has grown steadily as patients and clinicians seek non-hormonal options for sexual health. This guide covers the science, regulatory status, and how a telehealth evaluation works.
What Is PT-141 (Bremelanotide)?
PT-141 is the research name for bremelanotide — a cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (α-MSH). It binds to melanocortin receptors (MC3R and MC4R) in the central nervous system.
This central mechanism separates it from older sexual health therapies that rely on peripheral vascular effects.
FDA Approval Status
Bremelanotide is commercially available as Vyleesi®, FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women. That approval applies to the branded commercial product under its specific indication only.
Compounded versions of PT-141 are not FDA-approved. They are prepared under federal compounding regulations and require a provider-issued prescription following individual patient evaluation.
How PT-141 Differs from Conventional Options
PDE5 inhibitors (sildenafil, tadalafil) work by increasing blood flow to genital tissue. PT-141 acts upstream — at the brain level — to influence the desire pathway itself.
| Feature | PT-141 (Bremelanotide) | PDE5 Inhibitors |
|---|---|---|
| Mechanism | Central (melanocortin receptors) | Peripheral (blood flow) |
| Addresses desire/arousal? | Yes | Primarily physical response |
| Hormonal? | No | No |
| FDA-approved commercial use | HSDD in premenopausal women (Vyleesi®) | Erectile dysfunction (multiple brands) |
| Route | Subcutaneous injection or intranasal | Oral tablet |
PT-141 for Women: What Clinical Data Shows
The pivotal trials supporting Vyleesi® enrolled premenopausal women with HSDD. Published data (Simon et al., Obstetrics & Gynecology, 2019) demonstrated statistically significant increases in satisfying sexual events and reductions in distress associated with low desire, compared with placebo.
Those findings reflect the FDA-approved commercial product under its approved indication. Compounded formulations have not been evaluated in the same trials.
PT-141 for Men: Off-Label Research
Early clinical research has explored PT-141's effects on male sexual function. A study published in the Journal of Sexual Medicine (Safarinejad & Hosseini, 2008) found bremelanotide associated with significant improvements in erectile function scores in men who had not responded to sildenafil.
This research is preliminary. Compounded PT-141 for men is not FDA-approved. Individual results vary.
Who May Be a Candidate?
A licensed provider determines whether PT-141 is medically appropriate on a case-by-case basis. Patients who may initiate a discussion include:
- Premenopausal women with persistent low sexual desire not explained by another medical condition
- Men with low libido who have not responded to other interventions
- Patients seeking a non-hormonal approach to sexual health
- Individuals without uncontrolled hypertension (a contraindication noted in Vyleesi® labeling)
Approval is not guaranteed. A provider-issued prescription is required before any medication is dispensed.
Safety Considerations
Across bremelanotide clinical trials, common adverse effects included nausea, flushing, and transient blood pressure increases. The Vyleesi® label includes a contraindication for patients with known cardiovascular disease.
Compounded formulations carry additional considerations. Potency, purity, and sterility depend on the compounding pharmacy's quality standards. Individual results vary.
How the TelosRX Asynchronous Evaluation Works
TelosRX is an online-first, asynchronous telehealth service. No scheduled video appointment is required.
- Complete a detailed online intake form covering your health history and sexual health goals.
- A licensed provider reviews your submission and determines medical appropriateness.
- If approved, a prescription is issued and fulfilled through a licensed pharmacy.
The process happens on your schedule, at your pace.
Compounded PT-141 is not FDA-approved. It is prepared under federal compounding regulations for individual patients. Approval is not guaranteed. Individual results vary. TelosRX operates under LegitScript-certified telehealth standards as an online-first, asynchronous telehealth service.
Start your private evaluation at TelosRX.